News und Analysen
Half-year results 2025 of Sartorius Stedim Biotech
Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27
Following an announcement earlier this week, Agilent Technologies Inc. (NYSE: A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial
Humana Simplifies Access to Coverage and Care Information
Humana Inc. [NYSE: HUM] announced today its latest collaboration with healthcare software company Epic, becoming the first health insurer to integrate health plan information directly into the
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product
Agilent Announces CFO Transition
Agilent Technologies Inc. (NYSE: A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled
EQS-News: Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the
EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to
LivaNova to Announce Second-Quarter 2025 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m
Humana Foundation Responds to Central Texas Flood Tragedy with $500,000 in Recovery Support
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today a $500,000 donation to aid recovery efforts in Central Texas following the tragic flooding that struck over the
GenSight Biologics Reports Cash Position as of June 30, 2025
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and reminds
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Evolva Holding SA invites to an Extraordinary General Meeting 2025 to change name to EvoNext Holdings SA
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Humana Launches Medicaid Plan in Virginia
Humana Healthy Horizons is now a Medicaid plan option for Virginians covered by Virginia Cardinal Care.
“At Humana, we put our members’ health first, and we are committed to improving the